ERJ Open Research最新文献

{"title":"Real-world evidence of tezepelumab for severe asthma: a retrospective multicentre cohort.","authors":"Jasmin Khateeb, Mordechai R Kramer, Ophir Freund, Reem Mhameed, Eviatar Naamany, Aviv Kupershmidt, Gal Elkayam, Anna Breslavsky, Dror Rosengarten, Yaniv Dotan, Ori Wand, Amir Bar-Shai","doi":"10.1183/23120541.00314-2025","DOIUrl":"10.1183/23120541.00314-2025","url":null,"abstract":"<p><strong>Background: </strong>Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin, has demonstrated efficacy for severe asthma in clinical trials, but real-world evidence remains limited. We aimed to evaluate the characteristics and outcomes of patients initiating tezepelumab in a real-world setting.</p><p><strong>Methods: </strong>We conducted a retrospective, multicentre cohort study across four tertiary care centres to evaluate the real-world effectiveness of tezepelumab in patients with severe asthma. Eligible patients were adults with a confirmed diagnosis of severe asthma, treated with tezepelumab. Data on exacerbation rates, pulmonary function and corticosteroid use were collected and analysed at baseline and 1-year follow-up.</p><p><strong>Results: </strong>The study included 103 patients treated with tezepelumab with a median (interquartile range) duration of 323 (267-359) days. Overall, 39% had prior biologic therapy and 32% had an eosinophil count <300 cells·μL^-1. At follow-up, there was a 66.7% relative reduction in annual exacerbations. The most pronounced reduction was observed in biologic-naïve patients with peripheral eosinophil counts ≥300 cells·μL^-1 (78% reduction). A 62% relative reduction was found among patients with eosinophil counts <150 cells·μL^-1. There were significant improvements in forced expiratory volume in 1 s, with 51% of patients demonstrating a ≥10% relative increase. Of patients using maintenance oral corticosteroid (mOCS), 45% discontinued mOCS and 23% reduced their dose by more than 50%.</p><p><strong>Conclusions: </strong>In this real-world cohort, treatment with tezepelumab for a median of 46 weeks was associated with improved asthma control, reductions in exacerbations, mOCS and inhaled corticosteroid doses, and a low symptom burden. These findings were consistent in biologic-experienced or low-eosinophil patients.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 5","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methicillin-resistant <i>Staphylococcus aureus</i> and pulmonary outcome in people with cystic fibrosis: a European Cystic Fibrosis Patient Registry data analysis.","authors":"Meir Mei-Zahav, Miri Dotan, Luigi Annicchiarico, Annalisa Orenti, Dario Prais","doi":"10.1183/23120541.01284-2024","DOIUrl":"10.1183/23120541.01284-2024","url":null,"abstract":"<p><p><b>MRSA in CF patients is linked to worse lung function, longer <i>i.v.</i> antibiotic treatments, increased hospital stays and higher risks of complications. This underscores the importance of continuous MRSA monitoring and targeted interventions in CF care.</b> https://bit.ly/43Gjjpt.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 5","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400180/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Viruses in bronchiectasis.","authors":"Claire Baker, James D Chalmers","doi":"10.1183/23120541.01131-2024","DOIUrl":"10.1183/23120541.01131-2024","url":null,"abstract":"<p><p>Bronchiectasis is a chronic respiratory condition characterised by irreversible dilation of the bronchi, leading to recurrent respiratory infections and chronic inflammation. Bacterial infections have been well-recognised as contributors to disease progression as well as potent inducers of exacerbations for decades. However, recent studies have indicated that viruses are present in up to 50% of exacerbations, raising questions over the role viruses may play in bronchiectasis. Despite the evidence of their presence, the role of viral infections in bronchiectasis remains largely underexplored. Understanding how viruses impact bronchiectasis is crucial in providing patients with better care and treatment strategies. Given the persistent threat of viral infections, as highlighted by the coronavirus disease 2019 (COVID-19) pandemic, this review aims to provide an overview of the current knowledge surrounding viruses in bronchiectasis, how they may trigger exacerbations and insights from other chronic respiratory conditions where the role of viruses is better understood.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 5","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing severe asthma care: real-world outcomes of a digital adherence and self-management platform.","authors":"Laura Wiffen, Lynn Elsey, Thomas P Brown, James Hadwin, Milan Chauhan, Ina Kostakis, Stephen Fowler, Anoop J Chauhan","doi":"10.1183/23120541.01178-2024","DOIUrl":"10.1183/23120541.01178-2024","url":null,"abstract":"<p><p><b>Integrating digital adherence and self-management tools into standard care can improve asthma control, quality of life and healthcare utilisation, particularly in patients with suboptimal adherence</b> https://bit.ly/41FuddG.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 5","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹H-NMR urine metabolomic fingerprint for severity discrimination in pulmonary sarcoidosis.","authors":"Florence Jeny, Mohamed Nawfal Triba, Simon Chauveau, Dominique Valeyre, Sabrina Mokhtari, Hilario Nunes, Jean-Francois Bernaudin, Philippe Savarin","doi":"10.1183/23120541.00763-2024","DOIUrl":"10.1183/23120541.00763-2024","url":null,"abstract":"<p><strong>Background: </strong>Sarcoidosis is a systemic inflammatory immune disease characterised by noncaseating granulomas. Its course can vary from benign to very severe, requiring appropriate treatment. Few biomarkers are available to monitor the management of these patients and to identify those at risk of poor prognosis. Given the systemic nature of sarcoidosis, we hypothesised that the analysis of urine metabolites could provide valuable biomarkers for the management of severe disease.</p><p><strong>Methods: </strong>We conducted a comparative analysis of urine metabolomics in a consecutive cohort of 37 well-phenotyped patients, using ¹H nuclear magnetic resonance (NMR) with multivariate statistical analysis, followed by metabolite identification. After NMR spectra acquisition, we used principal component analysis and partial least squares (PLS) discriminant analysis to generate predictive models.</p><p><strong>Results: </strong>A urinary metabolomic signature predictive of severe pulmonary sarcoidosis was identified using a PLS model. We selected five metabolites with significant changes in samples from severe sarcoidosis defined by a composite physiologic index >40 compared to those from nonsevere sarcoidosis. These changes correspond to the decreased levels of taurine, hippurate, serine and creatinine and increased levels of 3-hydroxyisovalerate. This metabolite profile suggests an association with activated inflammatory pathways.</p><p><strong>Conclusions: </strong>This study shows that urinary NMR metabolites can discriminate samples between nonsevere and severe sarcoidosis. It suggests that urinary metabolomic studies in sarcoidosis may be particularly useful to identify potentially relevant biomarkers. However, further validation in a larger cohort of patients at different disease stages is warranted to confirm the relevance of these NMR biomarkers for follow-up.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 4","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urinary thromboxane and isoprostane levels are elevated in symptom-high T2-biomarker-low severe asthma.","authors":"Matthew Chad Eastwood, John Busby, Johan Kolmert, Javier Zurita, Sven-Erik Dahlén, Pamela Jane McDowell, Judy Bradley, David Jackson, Ian Pavord, Ratko Djukanovic, Joseph Arron, Peter Bradding, Chris Brightling, Rekha Chaudhuri, Douglas Cowan, Stephen Fowler, Timothy Colin Hardman, Cecile Holweg, James Lordan, Adel Mansur, Douglas Robinson, Craig E Wheelock, Liam Heaney","doi":"10.1183/23120541.01089-2024","DOIUrl":"10.1183/23120541.01089-2024","url":null,"abstract":"<p><strong>Background: </strong>∼5-10% of patients with asthma have severe disease. A proportion remain symptomatic despite suppression of T2-related inflammation but what drives persistent symptoms remains unclear. Eicosanoids exert a functional role in pulmonary inflammation. We explored the relationship between urinary eicosanoids, asthma symptoms, obesity and T2-biomarker status.</p><p><strong>Methods: </strong>Urine was sampled during a randomised controlled trial assessing corticosteroid optimisation using T2-biomarker directed care at scheduled study visits (n=728) and at exacerbation (n=103). Urine eicosanoid concentrations were measured by mass spectrometry, then log2-transformed, z-scored and concatenated by biosynthetic pathway generating six pathway scores. Results were stratified by T2 status (T2-low: exhaled nitric oxide fraction (<i>F</i> _ENO) <20 ppb and blood eosinophil count (BEC) <0.15×10⁹ cells·L^-1; <i>versus</i> T2-high: <i>F</i> _ENO ≥20 ppb and BEC ≥0.15×10⁹ cells·L^-1), symptoms (symptom-low: Asthma Control Questionnaire-7 (ACQ-7) <1.5; <i>versus</i> symptom-high: ACQ-7 ≥1.5) and obesity.</p><p><strong>Results: </strong>Isoprostane (pathway score p=0.02) and thromboxane (pathway score p=0.04) levels were higher in symptom-high <i>versus</i> symptom-low, T2-low participants. Isoprostane levels were greater in symptom-high <i>versus</i> symptom-low participants, irrespective of T2 status (pathway score p=0.01). Cysteinyl-leukotriene E₄ levels (LTE₄) were elevated in T2-high <i>versus</i> T2-low participants (pathway score p=0.0007), irrespective of symptoms. Corticosteroid exposure, obesity and exacerbations were not associated with increased eicosanoid levels (p≥0.05).</p><p><strong>Conclusion: </strong>Raised urinary eicosanoid levels of isoprostanes and thromboxanes were associated with increased symptoms in T2-low severe asthma. Elevated excretion of these metabolites in T2-low participants could reflect increased thromboxane-receptor (TP) activation, which may be promoting increased asthma severity and bronchoconstriction. Further research and interventions are needed to explore the role of TP modulation in T2-low severe asthma.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 4","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers of type 2 inflammation as predictors of response to biologics for severe eosinophilic asthma.","authors":"Duong Duc Pham, Ji-Hyang Lee, Hyouk-Soo Kwon, Woo-Jung Song, You Sook Cho, Hyunkyoung Kim, Jae-Woo Kwon, So-Young Park, Sujeong Kim, Gyu Young Hur, Byung Keun Kim, Young-Hee Nam, Min-Suk Yang, Mi-Yeong Kim, Sae-Hoon Kim, Byung-Jae Lee, Taehoon Lee, So Young Park, Min-Hye Kim, Young-Joo Cho, ChanSun Park, Jae-Woo Jung, Han Ki Park, Joo-Hee Kim, Ji-Yong Moon, Pankaj Bhavsar, Ian M Adcock, Kian Fan Chung, Tae-Bum Kim","doi":"10.1183/23120541.00969-2024","DOIUrl":"10.1183/23120541.00969-2024","url":null,"abstract":"<p><strong>Background: </strong>The relationship between pre-treatment levels of blood eosinophil count (BEC), fractional exhaled nitric oxide (<i>F</i> _ENO) and sputum eosinophils (Sp-EOS) and treatment response to monoclonal antibodies (mAbs) in severe eosinophilic asthma (SEA) remains unclear. We evaluated pre-treatment levels of BEC, <i>F</i> _ENO, Sp-EOS and their combinations as predictors of treatment responses in patients with SEA undergoing anti-interleukin (IL)-5/IL-5Rα or anti-IL-4Rα antibody therapies.</p><p><strong>Methods: </strong>The study included 153 adult patients with SEA (59 anti-IL-5/IL-5Rα and 94 anti-IL-4Rα users). Logistic regression models were used to evaluate the association between predictors and 12-month treatment responses and clinical remission across four domains: exacerbation rate, maintenance of oral corticosteroid dose, forced expiratory volume in 1 s (FEV₁) and asthma control test (ACT) improvement.</p><p><strong>Results: </strong>Pre-treatment BEC and Sp-EOS were not associated with treatment responses in either mAb group. For combined data from anti-IL-5/IL-5Rα and anti-IL-4Rα users, the adjusted odds ratios (95% confidence intervals) for a 1-unit increase in log-transformed <i>F</i> _ENO were 1.8 (1.21-2.74) for FEV₁ response and 2.15 (1.29-3.75) for ACT response. For anti-IL-4Rα users, these values were 2.34 (1.39-4.17) and 3.6 (1.73-8.84), respectively. No significant association between <i>F</i> _ENO and treatment response was found among anti-IL-5/IL-5Rα users. Additionally, no associations were observed between BEC, Sp-EOS or <i>F</i> _ENO and clinical remission across mAb categories. Combining biomarkers did not significantly enhance predictive ability.</p><p><strong>Conclusion: </strong>In patients with SEA treated with anti-IL-4Rα antibodies, pre-treatment <i>F</i> _ENO may be a good predictor for certain treatment response domains.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 4","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhaled nitric oxide for the treatment of COVID-19: an open-label, parallel, randomised controlled trial.","authors":"Frederico Friedrich, Marcelo Cypel, Vinicius Schenk Michaelsen, Marcos Otávio Antunes Brum, Fabiano Ramos, Roberta Marco, Gustavo Chatkin, Lucas Kich Grun, Letícya Simone Melo Dos Santos, Amanda Paz Santos, Morgana Thaís Carollo Fernandes, Luciana Medeiros Paungartner, Marcelo Scheffer Maranghello, Caroline Lantmann, Gustavo Eggers, Gustavo Duenhas Sanches, Daniel Marinowic, Regis Goulart Rosa, Florencia María Barbé-Tuana, Marcus Herbert Jones","doi":"10.1183/23120541.00006-2024","DOIUrl":"10.1183/23120541.00006-2024","url":null,"abstract":"<p><strong>Background: </strong>Inhaled nitric oxide (iNO) in high concentration inhibits SARS-CoV-2 replication in epithelial cells and may prevent severe disease in hospitalised patients. The aim of this study was to evaluate safety and efficacy of iNO 160 ppm on supplemental oxygen in patients hospitalised with COVID-19.</p><p><strong>Methods: </strong>We conducted an open-label, randomised clinical trial in hospitalised patients with COVID-19 receiving supplemental oxygen. Patients were randomly assigned to receive iNO for 6 h in addition to standard of care. The primary safety end-point was assessed by incidence of adverse events. The secondary efficacy end-point was the number of days free of supplemental oxygen within 15 days after randomisation.</p><p><strong>Results: </strong>55 patients were enrolled, 27 in the iNO group and 27 in the control group, and one patient was excluded. No adverse events occurred with the inhalation of nitric oxide. Median (IQR) number of days free of supplemental oxygen was 11 (8.0-13.0) in the iNO group and 8 (2.5-10.5) in the control group (p=0.044). The iNO group had a shorter length of hospital stay (4.5 days (3.0-6.3) compared to 7.0 days (6.0-10.0) in the control group; p=0.004). Clinical score was lower in the iNO group on days 3 and 5 (p=0.010 and p=0.033). The number of patients weaned from ventilatory support on day 3 was higher in the iNO group (n=9 (33%)) when compared to controls (n=1 (4%)); p=0.005. Respiratory failure and mortality did not differ between the groups.</p><p><strong>Conclusion: </strong>The iNO treatment was well tolerated and safe. Among adults hospitalised for COVID-19, iNO 160 ppm for 6 h increased the number of days free from supplemental oxygen, shortened the days of ventilatory support and the length of hospital stay, and improved the clinical score.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 4","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378598/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary function in children post-empyema: spirometry <i>versus</i> lung clearance index.","authors":"Mehmet Cihan Senturk, Yasemin Gokdemir, Almala Pinar Ergenekon, Zeynep Meva Altas, Ela Erdem Eralp, Cansu Yilmaz Yegit, Muruvvet Cenk, Mine Kalyoncu, Gursu Kiyan, Saniye Girit Kanmis, Emine Atag, Seda Geylani Gulec, Fazilet Karakoc, Bulent Karadag","doi":"10.1183/23120541.00855-2024","DOIUrl":"10.1183/23120541.00855-2024","url":null,"abstract":"<p><strong>Background: </strong>We hypothesise that the lung clearance index (LCI) would be superior to spirometry in diagnosing early-stage respiratory diseases earlier and, more precisely, in patients who received medical or surgical treatment for empyema.</p><p><strong>Methods: </strong>Children over 5 years old diagnosed with empyema at least 6 months ago were recruited. In addition, a control group was created from healthy individuals between the ages of 5-18 years. Spirometry and LCI were performed in both groups.</p><p><strong>Results: </strong>The spirometric values of the patients were compared with the spirometric values of the controls; there was no significant difference between the patient and control groups' forced expiratory volume in 1 s (FEV₁), forced vital capacity (FVC) and FEV₁/FVC z scores results when compared (p=0.610, p=0.342 and p=0.298, respectively). In addition, when the LCI 2.5% values of the patients were compared with the LCI 2.5% values of the controls and reference values, the LCI 2.5% was found to be significantly abnormal (p=0.003 and p=0.005, respectively).</p><p><strong>Conclusion: </strong>In the long-term follow-up of patients who received inpatient treatment for empyema, airway disease that could not be detected by spirometry was obtained using the LCI method.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 4","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Pseudomonas aeruginosa</i> infection is linked to increases in cardiovascular events post exacerbation in bronchiectasis.","authors":"Engin L, Caroline A Owen, Fred Reid, Claudia Cabrera, Charles S Haworth, Rod Hughes","doi":"10.1183/23120541.01126-2024","DOIUrl":"10.1183/23120541.01126-2024","url":null,"abstract":"<p><strong>Introduction: </strong><i>Pseudomonas aeruginosa</i> (PsA) infection contributes to disease progression in bronchiectasis (BE), particularly exacerbations which are known to increase the risk of cardiovascular (CV) events. However, the link between PsA infection and CV events in BE is unknown. Thus, we investigated whether there is an association between PsA airway infection and the risk of CV events post-exacerbation.</p><p><strong>Methods: </strong>This was a US retrospective cohort study using the TriNetX platform between 2008 and 2019. Adult patients with (wPsA) or without (w/oPsA) PsA airway infection were included. Date of first exacerbation corresponded to the index date, and patients were followed for up to 5 years post index. Risk ratios (RR) for hospitalisation, subsequent exacerbation, mortality and incidence of pre-specified CV events were estimated. Propensity score matching (PSM) was used to balance baseline characteristics.</p><p><strong>Results: </strong>After PSM, patients wPsA infection were at a greater risk of hospitalisation (RR: 1.40; 95% CI: 1.19-1.64), subsequent exacerbation (RR: 1.70; 95% CI: 1.53-1.90) and mortality (RR: 1.37; 95% CI: 1.20-1.56) than patients w/oPsA. PsA infection was associated with a higher risk of dysrhythmias (RR: 1.32; 95% CI: 1.13-1.54), inflammatory heart disease (RR: 2.09; 95% CI: 1.29-3.37), other cardiac disorders (RR: 1.40; 95% CI: 1.14-1.72), thrombotic disorders (RR: 1.31; 95% CI: 1.01-1.68), major adverse cardiovascular events (RR: 1.35; 95% CI: 1.19-1.52) and any CV outcome (RR: 1.42; 95% CI: 1.24-1.62).</p><p><strong>Conclusion: </strong>PsA infection in patients with BE is associated with an increased risk of CV events following a baseline exacerbation. These data highlight the multisystemic nature of BE and the need to raise awareness of the potential increased risk of CV events in patients with BE experiencing exacerbations.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 4","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378861/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}